TNF receptor superfamily member 1A
Zuletzt aktualisiert 18. Aug 2020
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Der TNFRSF1A gene provides instructions for making a protein called tumour necrosis factor receptor 1 (TNFR1). This protein is found spanning the membrane of cells, with part of the TNFR1 protein outside the cell and part of the protein inside the cell. Outside the cell, the TNFR1 protein attaches (binds) to another protein called tumour necrosis factor (TNF). The interaction of the TNF protein with the TNFR1 protein causes the TNFR1 protein to bind to two other TNFR1 proteins, forming a three-protein complex called a trimer. This trimer formation is necessary for the TNFR1 protein to be functional.
Normal function
Der TNFRSF1A gene provides instructions for making a protein called tumour necrosis factor receptor 1 (TNFR1). This protein is found spanning the membrane of cells, with part of the TNFR1 protein outside the cell and part of the protein inside the cell. Outside the cell, the TNFR1 protein attaches (binds) to another protein called tumour necrosis factor (TNF). The interaction of the TNF protein with the TNFR1 protein causes the TNFR1 protein to bind to two other TNFR1 proteins, forming a three-protein complex called a trimer. This trimer formation is necessary for the TNFR1 protein to be functional.
The binding of the TNF and TNFR1 proteins causes the TNFR1 protein to send signals inside the cell. Signaling from the TNFR1 protein can trigger either inflammation or self-destruction of the cell (apoptosis). Signaling within the cell initiates a pathway that turns on a protein called nuclear factor kappa B, which triggers inflammation and leads to the production of immune system proteins called cytokines. Apoptosis is initiated when the TNFR1 protein, bound to the TNF protein, is brought into the cell and starts a process known as the caspase cascade.
Conditions referring to this gene or chromosome
Other names
p55
p55-R
TNF-R
TNF-R1
TNF-R55
TNFR-I
TNFR1
TNFR55
TNR1A_HUMAN
tumour necrosis factor binding protein 1
tumour necrosis factor receptor superfamily member 1A
tumour necrosis factor receptor superfamily, member 1A
tumour necrosis factor receptor type 1
tumour necrosis factor-alpha receptor
Related patient information and medicines

Patient information leaflet
Hidradenitis suppurativa
Hidradenitis suppurativa is a long-term (chronic) skin condition that leads to painful and repeated lumps of pus (boils or abscesses). Hidradenitis suppurativa tends to run in families; about one-third of people with hidradenitis suppurative habe ein family member who is affected. The most promising of these treatments are monoclonal antibodies,.

Patient information leaflet
Biologische Arzneimittel gegen rheumatoide Arthritis
Biological medicines mimic substances produced by the human body, such as antibodies. For example, some of these biological medicines block a chemical called tumour necrosis factor alpha (TNF-alpha) which plays an important role in causing inflammation in the joints. Medicines that block TNF include adalimumab, certolizumab pegol, etanercept,.

Patient information leaflet
Immunsuppression
Mycophenolate mofetil. Monoclonal antibodies - of which there are many ending in "mab", such as bevacizumab, rituximab and trastuzumab. Anti-TNF drugs such as etanercept , infliximab, adalimumab, certolizumab and golimumab. (TNF stands for anti tumour necrosis factor, and some of the "mab" medicines above act against TNF, so there is some overlap.

Patient information leaflet
Axiale Spondyloarthritis
Axiale Spondyloarthritis (auch bekannt als axSpA oder axi. Biological medicines Biologics can be used to control the disease process. The main ones used for axial spondyloarthritis are called tumour necrosis factor (TNF) inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab or infliximab). Other medicines, such as secukinumab, bimekizumab or.

Patient information leaflet
Morbus Bechterew
Ankylosing spondylitis is an auto-immune disease. In ankylosing spondylitis, a chemical called cytokine tumour necrosis factor alpha (TNF-alpha) is involved in causing inflammation. ...bitorsTNF-alpha inhibitors are also sometimes called anti-TNF-alpha drugs. In the UK the National Institute for Health and Care Excellence (NICE) recommends that.

Patient information leaflet
Psoriasis-Arthritis
Some DMARDs also have a beneficial effect on reducing the rash of psoriasis. Newer disease-modifying medicines A new class of recently developed medicines modify the effect of TNF alpha. The chemical TNF alpha plays an important role in causing inflammation in joints and skin. Blocking the effect of TNF alpha has been shown to reduce damage to.
Weiterführende Lektüre und Referenzen
- TNF receptor superfamily member 1A; MedlinePlus, National Library of Medicine.
- Kimberley FC, Lobito AA, Siegel RM, Screaton GR. Falling into TRAPS--receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. Arthritis Res Ther. 2007;9(4):217. doi: 10.1186/ar2197.
- Masson C, Simon V, Hoppe E, Insalaco P, Cisse I, Audran M. Tumor necrosis factor receptor-associated periodic syndrome (TRAPS): definition, semiology, prognosis, pathogenesis, treatment, and place relative to other periodic joint diseases. Joint Bone Spine. 2004 Jul;71(4):284-90. doi: 10.1016/j.jbspin.2003.10.008.
- Pettersson T, Kantonen J, Matikainen S, Repo H. Setting up TRAPS. Ann Med. 2012 Mar;44(2):109-18. doi: 10.3109/07853890.2010.548399. Epub 2011 Feb 1.
- Rebelo SL, Bainbridge SE, Amel-Kashipaz MR, Radford PM, Powell RJ, Todd I, Tighe PJ. Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum. 2006 Aug;54(8):2674-87. doi: 10.1002/art.21964.
- Stojanov S, McDermott MF. The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med. 2005 Oct 10;7(22):1-18. doi: 10.1017/S1462399405009749.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
18. Aug 2020 | Neueste Version
1 Aug 2011 | Ursprünglich veröffentlicht
Nehmen Sie an der Diskussion teil
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.

Fragen, teilen, verbinden.
Durchsuchen Sie Diskussionen, stellen Sie Fragen und teilen Sie Erfahrungen zu Hunderten von Gesundheitsthemen.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.